ReviewMolecular diversity2026
Natural products mediate ferroptosis and immune microenvironment-linked sensitization in osteosarcoma: from chemotherapy resistance to combined therapeutic transformation.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Osteosarcoma is a primary bone tumor in adolescents and young adults, characterized by high chemotherapy resistance and poor prognosis. Ferroptosis, an iron‑dependent and lipid-peroxidation‑driven cell death, has become a key target to overcome chemoresistance and inhibit tumor progression. Natural products, with structural diversity, multi‑target regulation, and low toxicity, show great potential in ferroptosis‑based osteosarcoma therapy. This review summarizes the core molecular mechanisms of ferroptosis, focusing on the regulatory networks of Xc⁻-GSH-GPX4, Nrf2/HMOX1, p53, MAPK, and STAT3 pathways in osteosarcoma. It further categorizes natural products (flavonoids, terpenoids, alkaloids, naphthoquinones, and isothiocyanates) and discusses their targets and mechanisms in inducing ferroptosis. Current bottlenecks, including insufficient mechanistic validation, poor target specificity, limited clinical translation, and a lack of combination therapy strategies, are critically assessed. Future research directions are also proposed. This review aims to provide a theoretical basis and new insights for developing natural-product-based ferroptosis‑targeting drugs to address clinical treatment dilemmas in osteosarcoma.
Indexed as
Identifiers
42665766What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.